A phase III trial of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs APL 2 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- 19 Mar 2018 According to an Apellis Pharmaceuticals media release, the remains on track to begin this study in the second half of 2018.
- 06 Jul 2017 New trial record
- 29 Jun 2017 According to an Apellis Pharmaceuticals media release, this trial is planned for the fourth quarter of 2017.